SG11201806946VA - Epigenomic profiling reveals the somatic promoter landscape of primary gastric adenocarcinoma - Google Patents

Epigenomic profiling reveals the somatic promoter landscape of primary gastric adenocarcinoma

Info

Publication number
SG11201806946VA
SG11201806946VA SG11201806946VA SG11201806946VA SG11201806946VA SG 11201806946V A SG11201806946V A SG 11201806946VA SG 11201806946V A SG11201806946V A SG 11201806946VA SG 11201806946V A SG11201806946V A SG 11201806946VA SG 11201806946V A SG11201806946V A SG 11201806946VA
Authority
SG
Singapore
Prior art keywords
singapore
genome
international
biopolis
street
Prior art date
Application number
SG11201806946VA
Other languages
English (en)
Inventor
Patrick Tan
Aditi Qamra
Manjie Xing
Wen Fong Ooi
Original Assignee
Agency Science Tech & Res
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Agency Science Tech & Res filed Critical Agency Science Tech & Res
Publication of SG11201806946VA publication Critical patent/SG11201806946VA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6875—Nucleoproteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/118—Prognosis of disease development
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/154—Methylation markers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • General Health & Medical Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Genetics & Genomics (AREA)
  • Cell Biology (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Medicinal Chemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
SG11201806946VA 2016-02-16 2017-02-16 Epigenomic profiling reveals the somatic promoter landscape of primary gastric adenocarcinoma SG11201806946VA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SG10201601142V 2016-02-16
PCT/SG2017/050072 WO2017142484A1 (fr) 2016-02-16 2017-02-16 Profilage épigénomique révélant le paysage de promoteur somatique d'adénocarcinome gastrique primaire

Publications (1)

Publication Number Publication Date
SG11201806946VA true SG11201806946VA (en) 2018-09-27

Family

ID=59626220

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201806946VA SG11201806946VA (en) 2016-02-16 2017-02-16 Epigenomic profiling reveals the somatic promoter landscape of primary gastric adenocarcinoma

Country Status (7)

Country Link
US (1) US20210301348A1 (fr)
EP (1) EP3417296B1 (fr)
JP (2) JP7336193B2 (fr)
KR (1) KR20180110133A (fr)
CN (1) CN109073659B (fr)
SG (1) SG11201806946VA (fr)
WO (1) WO2017142484A1 (fr)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019178214A1 (fr) * 2018-03-13 2019-09-19 Baylor Research Institute Procédés et compositions liés à la méthylation et à la récurrence chez des patients atteints d'un cancer gastrique
CN109880902B (zh) * 2018-10-11 2022-10-28 中国药科大学 一种长链非编码rna rp11-499f3.2在逆转肿瘤西妥昔单抗耐药治疗中的应用
US20220081723A1 (en) * 2018-12-21 2022-03-17 Agency For Science, Technology And Research Method of predicting for benefit from immune checkpoint inhibition therapy
CN109880894A (zh) * 2019-03-05 2019-06-14 杭州西合森医学检验实验室有限公司 基于RNAseq的肿瘤免疫微环境预测模型的构建方法
CN111863126B (zh) * 2020-05-28 2024-03-26 上海市生物医药技术研究院 构建结直肠肿瘤状态评估模型的方法及应用
CN111798919B (zh) * 2020-06-24 2022-11-25 上海交通大学 一种肿瘤新抗原预测方法、预测装置及存储介质
CN112877433B (zh) * 2021-02-08 2022-05-31 苏州瑞峰医药研发有限公司 一种结直肠癌靶向治疗药物
WO2024076285A1 (fr) * 2022-10-05 2024-04-11 Ivarsson Ylva Peptide ciblant la protéine nsp9 du sars-cov-2

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0601538D0 (en) 2006-01-26 2006-03-08 Univ Birmingham Epigenetic analysis
WO2011137302A1 (fr) * 2010-04-29 2011-11-03 The General Hospital Corporation Procédés d'identification de voies de signalisation intracellulaire régulées de manière aberrante dans des cellules cancéreuses
US9797002B2 (en) * 2010-06-25 2017-10-24 University Of Southern California Methods and kits for genome-wide methylation of GpC sites and genome-wide determination of chromatin structure
SG11201605259QA (en) * 2013-12-30 2016-07-28 Agency Science Tech & Res Methods for measuring biomarkers in gastrointestinal cancer
KR20170020463A (ko) 2014-06-19 2017-02-22 메모리얼 슬로안-케터링 캔서 센터 Ezh2 저해제에의 반응에 대한 바이오마커

Also Published As

Publication number Publication date
WO2017142484A1 (fr) 2017-08-24
KR20180110133A (ko) 2018-10-08
EP3417296B1 (fr) 2021-08-25
US20210301348A1 (en) 2021-09-30
EP3417296A4 (fr) 2019-12-11
CN109073659B (zh) 2022-05-17
CN109073659A (zh) 2018-12-21
EP3417296A1 (fr) 2018-12-26
JP7336193B2 (ja) 2023-08-31
JP2019511209A (ja) 2019-04-25
JP2022037137A (ja) 2022-03-08

Similar Documents

Publication Publication Date Title
SG11201806946VA (en) Epigenomic profiling reveals the somatic promoter landscape of primary gastric adenocarcinoma
SG11201809913PA (en) Methods for detecting target nucleic acids in a sample
SG11201805795WA (en) Systems and methods for securing and disseminating time sensitive information using a blockchain
SG11201808740TA (en) Multiplex nucleic acid assay methods capable of detecting closely related alleles, and reagents therefor
SG11201909652WA (en) Neoantigen identification, manufacture, and use
SG11201908564RA (en) Devices, processes, and systems for determination of nucleic acid sequence, expression, copy number, or methylation changes using combined nuclease, ligase, polymerase, and sequencing reactions
SG11201807334SA (en) Methods, compositions, and devices for information storage
SG11201811740WA (en) Systems and methods for identifying risky driving behavior
SG11201903271UA (en) Method and systems for the indexing of bioinformatics data
SG11201806282XA (en) High-throughput identification of patient-specific neoepitopes as therapeutic targets for cancer immunotherapies
SG11201903519UA (en) Methods and systems for barcoding nucleic acid molecules from individual cells or cell populations
SG11201810003UA (en) Using programmable dna binding proteins to enhance targeted genome modification
SG11201903830TA (en) Blockade of cd7 expression and chimeric antigen receptors for immunotherapy of t-cell malignancies
SG11201901126UA (en) Combination therapy for cancer
SG11201810611YA (en) Coumarin compounds and their uses as fluorescent labels
SG11201808494TA (en) Signal light detection
SG11201805835WA (en) Modified oncolytic virus
SG11201803703UA (en) Anti-complement factor c1q fab fragments and uses thereof
SG11201408489PA (en) Target detection and signal amplification
SG11201804712PA (en) Biofuel
SG11201811765TA (en) Methods and systems for providing transportation service
SG11201806945SA (en) Cancer epigenetic profiling
SG11201908127WA (en) Method for producing multispecific antibodies
SG11201805115PA (en) Detection and quantification of target nucleic acid sequence of a microorganism
SG11201903139SA (en) Methods for expression profile classification